| Management target | Revenue 15.0% FY27 |
|---|
| Revenue growth | 21% YoY revenue growth driven by volume expansion and genomics. |
|---|---|
| Margins | EBITDA margins expanded to 36%; mature centers at 40.9%. |
| Demand visibility | Strong, specifically in specialized genomics and pathology across Eastern India. |
| Management confidence | Confident, highlighting strong execution in expansion and genomics adoption. |
Growth
Revenue grew 21% YoY; genomics vertical surged 136% YoY; EBITDA margins expanded to 36% from 34%.
Outlook
Management guides for 15% revenue growth for FY27 and plans to reach 100 centers by FY28.
Risks
Seasonal weakness in Q3; regional concentration in Eastern India; margin pressure from rapid new center ramp-ups.
Last quarter's promises, checked
Delivered
- Guided 15% revenue growth → delivered 21% (= BEAT)
- Guided 33% EBITDA margin → delivered 36% (= BEAT)
- Guided 5 hubs and 8 spokes addition → delivered 10 centers (= BEAT)
Partly delivered
- Guided INR 70Cr capex → delivered INR 70-80Cr range (= PARTIAL)
Earnings Call Transcript filed with BSE, NSE: SURAKSHA. Summary written with AI assistance from the document.
Suraksha Diagnostic Ltd: key numbers
- Share price
- ₹343.30
- Market cap
- ₹1,788 Cr
- Revenue (annual)
- ₹310.4 Cr
- Net profit (annual)
- ₹32.19 Cr
- P/E (TTM)
- 50.0×Sector 57.8×
- Promoter holding
- 49.10%+0.00% QoQ
- FII holding
- 13.47%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Suraksha Diagnostic Ltd
All →Suraksha Diagnostic Annual General Meeting
Suraksha Diagnostic Ltd held its 21st AGM on September 22, 2026. Members adopted financial statements, approved a final dividend, and ratified cost auditor remuneration.
Suraksha Diagnostic Investor Presentation: Key Takeaways
Suraksha Diagnostic reported strong Q1 FY27 results with 21% YoY revenue growth and 14.7% PAT margin. Management is aggressively expanding the hub-and-spoke network beyond West Bengal into Jharkhand and Tripura.
Suraksha Diagnostic Q1 FY27 Results: Net Profit ₹12.8 Cr, Up 39.1% YoY
Suraksha Diagnostic Ltd reported revenue from operations of ₹87.6 Cr (+20.7% YoY) and net profit of ₹12.8 Cr (+39.1% YoY) for Q1 FY27.
- Key figure
- Net profit ₹12.8 Cr · +39.1% YoY
Suraksha Diagnostic Earnings Call: Key Takeaways
Suraksha Diagnostic Limited concluded FY26 with 23.1% revenue growth to INR 3104M. Strategy shifts towards specialized genomics and multi-state expansion into Bihar, Tripura, and Jharkhand.
Suraksha Diagnostic Earnings Call: Key Takeaways
Suraksha Diagnostic reported robust FY26 revenue growth of 23.1% YoY, driven by aggressive regional expansion and a shift toward high-value genomic and specialized radiology testing.
Suraksha Diagnostic Earnings Call: Key Takeaways
Suraksha Diagnostic reported robust FY26 results with 23% revenue growth and 16% EBITDA growth, driven by core diagnostic momentum and expansion in Eastern India.